Stage (next event)
Phase 2 (Top-line results)
Catalyst Info & Data Links
TITLE: Oral Korsuva for Atopic Dermatitis - Topline Data
ClinicalTrial.gov (NCT04018027): Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
07-09-2019 Phase 2 Initiation PR
May 2020: Corporate Presentation (slide 25-29)
MECHANISM OF ACTION
Opioid analgesics can act through three different types of opioid receptors, called mu, delta, and kappa. Morphine, the most widely used opioid analgesic, acts primarily via activation of the mu opioid receptor located in the central nervous system (CNS). This CNS action induces pain relief but is also associated with a wide array of CNS-mediated side effects including nausea/vomiting, sedation, respiratory depression, and abuse liability. As a way to avoid these undesirable CNS and mu opioid mediated side effects, there has been an effort to develop opioids which activate peripheral kappa opioid receptors present on sensory nerves, immune cells and the dorsal root ganglion (DRG). Such compounds, Kappa Opioid Receptor Agonists (KORAs), are thought to have the potential to provide pain relief (peripheral opioid analgesia) without producing significant CNS and mu-opioid mediated side effects.
DUPIXENT® (dupilumab) - Regeneron Pharmaceuticals, Inc.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post